Chief Financial Officer * · Aquestive Therapeutics, Inc. (AQST)

John Maxwell

A named executive officer of Aquestive Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,311,270

Salary $395,000Stock awards $0

FY2019: $1,054,123

1st of 3 named executive officers at Aquestive Therapeutics by FY2020 total.

3 named officers on file for Aquestive Therapeutics, FY2020

John Maxwell’s pay file — $29

  • 4 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aquestive Therapeutics’s whole pay program stands against its peers

  • Aquestive Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AQST→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 5, 2021 (DEF 14A).

Free

Get John Maxwell’s full pay file as a PDF — free

More than this page: up to 10 years of John’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

John Maxwell compensation by year

Aquestive Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Aquestive Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020
Salary$350,000$360,577$391,154$395,000
Bonus$70,000$0$0$0
Stock awards$874,335$0$0$0
Option awards$0$382,051$516,975$69,164
Non-equity incentive$306,250$278,964$119,490$0
Pension and deferred compensation$0$0$0$0
All other$19,615$866,774$26,504$847,106
Total$1,620,200$1,888,366$1,054,123$1,311,270

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aquestive Therapeutics, Inc. DEF 14A filed May 5, 2021, accession 0001140361-21-015985, and prior-year filings.

How this page was built: the Aquestive Therapeutics, Inc. filed document, accession 0001140361-21-015985. Every figure is read from that document and cited to the page and table it appears in. Filed May 5, 2021.

$1.6M
$1.9M
$1.1M
$1.3M
FY17
FY18
FY19
FY20
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Aquestive Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
John Maxwell · this pageChief Financial Officer *$1,311,270
Keith KendallChief Executive Officer$1,290,418
Daniel BarberChief Operating Officer$840,083

The full Aquestive Therapeutics compensation record

free company brief

This page is one person within Aquestive Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aquestive Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Maxwell's compensation dossier · One-time report. No refunds.